US · Consumer Cyclical · Personal Services
EPS came in at -0.19 against a street estimate of -0.40 — a beat of 52.5%.
Analysts rate MEDIFAST INC a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $12.00.
MIXED Medifast launched Trilivy and improved coach productivity, but revenue fell 19.4% as active coaches declined. Catalyst supports targeted Q4 profitability, though rebuilding the coach base remains the key risk. Q3 FY26 Analysts pressed management on the productivity-versus-coach-count tradeoff, GLP-1 competition and further SG&A savings. Management highlighted stronger field engagement, metabolic-health differentiation and additional AI-driven efficiency potential. 2026-10-26…
Full summary in the app.
| Fund | Stake |
|---|---|
| Renaissance Technologies Corp | 6.96% |
| Steamboat Capital Partners, LLC | 6.32% |
| Two Sigma Investments LLC | 4.30% |
| Vanguard Capital Management, LLC | 3.99% |
| Charles Schwab Investment Management Inc | 3.55% |
| BlackRock Inc | 3.30% |
| Dimensional Fund Advisors, Inc. | 3.25% |
| American Century Companies Inc | 2.85% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MEDIFAST INC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.